Heart Failure (HF) a common clinical condition characterized by either by a heart that does
not pump sufficiently or becomes stiff. A variety of mechanisms contribute to progressive
cardiac remodeling and dysfunction.
A new therapeutic approaches by preventing activation of the brain neuromodulatory pathway,
may lead to improve HF.
QCG001 is a prodrug of EC33, a aminopeptidase A (APA) inhibitor. QCG001 has been shown to be
an antihypertensive agent in animal models.
This study investigates the safety and efficacy of QGC001 in HF patients.